Brain Zaps and SSRI Withdrawal: What Are They?

What Brain Zaps Are and Why They Happen

Brain zaps are brief electric shock or jolt sensations in the head, often set off by eye movements, that many people report when lowering or stopping an antidepressant. They are a recognized withdrawal symptom, and a signal that the last reduction came faster than the brain could adjust.

They are also one of the strangest things a person can try to describe to a doctor. A jolt behind the eyes when you turn your head. A half-second where the room seems to stutter. Nothing on an examination, nothing on a scan, and no obvious words for it. People often go quiet about brain zaps because they sound like something invented, which is exactly the wrong outcome: the sensation carries useful clinical information about the pace of a dose reduction.

How People Describe Brain Zaps

There is no single description, because the sensation varies between people. In the published descriptive literature, brain zaps are reported as brief electrical or shock-like sensations in the head, sometimes with a momentary sense of the brain "switching off", sometimes accompanied by dizziness or a visual jolt, and often triggered or worsened by lateral eye movement (Papp & Onton, 2018; Papp & Onton, 2022). Some people feel them a handful of times a day. Others report them repeatedly within a single minute.

In medical notes they may be written down as paresthesia, which simply means an abnormal sensation with no external cause. Some people also feel them in the limbs rather than only the head. The honest summary of the evidence here is that the literature is small, mostly descriptive and largely drawn from surveys and case reports, so it tells us what brain zaps are like far better than it tells us why they happen.

Why Brain Zaps Happen When an Antidepressant Dose Comes Down

The mechanism is not settled. Researchers have proposed that brain zaps reflect a disturbance in electrical signaling between neurons, and comparisons have been drawn with shock-like sensations seen in some neurological conditions, but these remain hypotheses rather than established findings (Papp & Onton, 2018).

What is better understood is the broader process the zaps sit inside. When a drug that acts on the central nervous system is taken for months or years, the brain adapts to its presence and establishes a new working balance. When the drug is removed faster than those adaptations can reverse, the system is left briefly unopposed, and the result is a period of nervous system hyperexcitability. Withdrawal symptoms, including sensory ones, arise from that gap between how much drug the brain expects and how much it is getting (Horowitz & Taylor, 2019). This is also why the problem is one of rate rather than willpower, and why the pace of reduction matters more than the destination. We look at recovery from those adaptations in more detail in our guide to whether the brain goes back to normal after antidepressants.

Why "Discontinuation Syndrome" Is the Wrong Name for This

You will often see brain zaps filed under "antidepressant discontinuation syndrome". "Discontinuation syndrome" is a pharmaceutical-industry euphemism that shifts responsibility for the difficulty of stopping from the drug to the patient. It makes the difficulty sound like a property of the act of stopping rather than a consequence of the body having adapted to a drug. The more accurate and honest term is antidepressant withdrawal. Physical dependence, in the pharmacological sense, simply means the body has adapted and will react when the drug is reduced. It does not mean addiction, and it says nothing about a person's character or motivation.

Naming it correctly has a practical consequence. If the symptom is understood as withdrawal, the obvious response is to look at the size and timing of the dose reduction. If it is dismissed as a brief inconvenience of stopping, nobody adjusts anything.

Who Gets Brain Zaps, and What Makes Them More Likely

The most specific figures on brain zaps come from a 2024 survey of 1,148 people recruited through online antidepressant withdrawal support groups. In that survey, 76.8% reported electric shock sensations, or brain zaps, starting or getting worse after reducing or stopping an antidepressant, compared with 5.6% who had them in the weeks before they started the drug (Moncrieff et al., 2024). That contrast is the useful part: it ties zaps to coming off the drug rather than to the condition it was prescribed for. The sample was self-selected from peer support groups, which the authors say is not representative of everyone who stops, so the figure describes that group and should not be read as the share of all people who will get brain zaps.

Because brain zaps are one part of withdrawal, the wider withdrawal data are the best guide to who is at risk. Symptoms on stopping are common but not universal. A systematic review of 14 studies found that an average of 56% of people who stopped antidepressants experienced withdrawal effects, with a range across studies from 27% to 86% (Davies & Read, 2019). Severity varies just as widely: in the four large studies in that review that measured severity, an average of 46% of people who experienced withdrawal rated it at the most severe level offered.

A review of the published data found that longer duration of use, SNRIs and paroxetine, and a previous difficult experience of coming off are all associated with higher risk, while higher dose showed a weaker association (Horowitz et al., 2023). Dr. Mark Horowitz, an author of that review and of the 2024 survey above, is Outro Health's clinical co-founder. In a 2025 survey of 310 NHS primary care patients who had tried to stop an antidepressant, those who had taken the drug for more than two years were far more likely to experience a withdrawal syndrome, and severe withdrawal, than those who had taken it for under six months (Horowitz et al., 2025).

Speed matters too. Stopping abruptly, or dropping by a large fraction of the current dose in one step, gives the nervous system the least time to adjust.

Short Half-Life Drugs and What Half-Life Does Not Tell You

Brain zaps are reported particularly often with drugs that leave the bloodstream quickly, such as Effexor (venlafaxine), Paxil (paroxetine) and Cymbalta (duloxetine). With a short half-life, plasma levels fall steeply between doses and after a reduction, so the change registers fast. Our post on the Effexor withdrawal timeline covers that pattern in more detail, and the duloxetine version of this question is answered in our post on Cymbalta brain zaps.

The important caveat: half-life describes how quickly a drug clears the body, not how quickly the brain's adaptations reverse. Those are different clocks. A drug can be entirely gone within days while the changes the brain made to live with it over years are still resolving, which is why prolonged symptoms remain possible well after clearance.

Are Brain Zaps a Sign of Permanent Damage?

There is no evidence in the published literature that brain zaps cause or indicate lasting structural injury. That is an absence of evidence rather than proof of safety, and it is worth stating plainly rather than dressing up: the research base is small, descriptive and has not been designed to answer that question. The most defensible inference from what is currently available is that brain zaps are a transient sensory phenomenon linked to the pace of dose change, and that they settle as the brain adjusts to the absence of the medication.

How long that takes is highly individual. Some people have mild symptoms for days or weeks. Many have prolonged symptoms, which are frequently mistaken for relapse. In the review cited above, seven of ten studies reporting duration found that a significant proportion of people experience symptoms for more than two weeks, and it is not uncommon for them to last several months (Davies & Read, 2019). In the 2025 primary care survey, 20% of respondents reported symptoms lasting more than three months and 10% for more than a year (Horowitz et al., 2025).

If you are having thoughts of harming yourself at any point during a dose change, call or text 988 in the US for the Suicide and Crisis Lifeline. Do not stop a medication suddenly without clinical support.

Brain Zaps, Low Mood, and the Relapse Question

Withdrawal can include low mood, anxiety and tearfulness, which is why it is so often read as relapse.

"Withdrawal is the horse and relapse is the zebra."
Dr. Mark Horowitz, Clinical Co-Founder of Outro Health (Journey's Dream, 2024)

Two things help separate them. NICE advises that relapse does not usually happen as soon as someone stops or lowers an antidepressant, and that withdrawal can include symptoms that are not typical of depression, such as dizziness or electric-shock sensations (NICE, 2022). Brain zaps belong firmly in that second category. Depression does not produce a jolt in the head when you glance sideways.

Timing on its own is not decisive, though. Withdrawal symptoms can be delayed for several weeks or even months after a dose reduction or the last dose, something often called delayed onset withdrawal. It is best known with fluoxetine, whose active metabolite lingers for weeks, but it also happens with shorter-acting SSRIs and SNRIs, and it is one reason late symptoms get misread as relapse (Horowitz & Taylor, 2022).

This distinction is not something to settle alone. It is a conversation with the clinician who knows your history. Where relapse is a genuine concern, it is also worth knowing that most people recover from depression within a year, including those with severe episodes (Whiteford et al., 2013). Feeling depressed or anxious is real, and taking withdrawal seriously does not mean taking those feelings any less seriously.

Where Brain Zaps Fit in the Sequence of Symptoms

Brain zaps rarely arrive alone. They tend to appear alongside dizziness, nausea, sleep disturbance, irritability or heightened sensitivity to light and sound, clustering in the days after a reduction and easing as the system settles, though again the pattern is individual. We map the usual order of events in our overview of the phases of SSRI withdrawal. The practical point is that zaps are usually the most recognizable member of a group, so their arrival is a good moment to review the whole picture with a clinician rather than to wait and see.

What Tends to Help With Brain Zaps

Nothing reliably abolishes this symptom, and anyone who tells you otherwise is overselling. What clinicians can do is change the conditions that produce it: the size of each reduction and the time allowed between reductions.

Why Smaller Steps at Low Doses Make Pharmacological Sense

PET imaging shows that SSRIs occupy roughly 80% of serotonin transporters at their minimum therapeutic doses, with occupancy rising steeply at low doses and plateauing at higher ones (Meyer et al., 2004). Because of that curve, each milligram has a much larger effect on the target at the bottom of the dose range than at the top. Reducing by equal milligram amounts therefore produces progressively bigger jolts to the system as the dose gets lower. Reducing hyperbolically, by progressively smaller amounts, changes the drug's effect in roughly even steps instead (Horowitz & Taylor, 2019). This is a pharmacological rationale supported by observational tapering data, not a result proven in randomized trials.

The Shape of a Supported Taper

NICE recommends tapering in steps where each dose is a proportion of the previous one, with smaller reductions and liquid formulations as the dose gets lower (NICE, 2022). The Maudsley Deprescribing Guidelines describe the same shape and note that peer-led tapering communities, through years of trial and error, have found reductions of about 10% of the most recent dose, each smaller than the last, to be the most helpful, which closely approximates the schedules derived from receptor-occupancy data (Horowitz & Taylor, 2024). The book frames the cycle as an initial reduction sized to a person's estimated withdrawal risk, monitoring of what that reduction causes, and sizing the next step by how tolerable the last one was.

These figures are illustrative of a shape, not a plan. A clinician estimates risk and individualizes everything, including whether to reduce at all.

Steps a Clinician-Guided Process Usually Follows

1. The patient reports the zaps to the clinician, noting when they started relative to the last dose change.
2. The clinician and patient review that reduction together: how large it was as a proportion of the dose, and how long ago.
3. The clinician considers pausing at the current dose, or returning to the last dose that felt stable, until symptoms settle.
4. The clinician resumes with smaller steps, each sized as a proportion of the current dose rather than a fixed milligram amount.
5. Symptoms rather than the calendar set the interval between reductions.
6. The clinician and patient plan ahead for doses smaller than the lowest available tablet, which generally means a liquid or a compounded formulation.
7. The patient tracks symptoms between appointments so that the next decision is based on a record, not a memory.

Other Things People Try

Some people report trying omega-3 supplementation, acupuncture or manual therapies to take the edge off, though none of these has been studied specifically for brain zaps in people coming off these medications. Anything you add is worth raising with your clinician first. What we do not recommend is pushing through in silence, because the symptom is information and silence wastes it.

Who This Is for, and Who It Is Not For

• Useful if you are noticing zaps after a dose reduction and want to understand what your clinician is weighing up.
• Useful if you have been told this is a brief inconvenience and your experience has not matched that.
• Useful if you are considering coming off and want to know what a careful process looks like before you start the conversation.
• Not a substitute for clinical assessment, and not a schedule to follow on your own.
• Not relevant to decisions about starting or increasing a medication, which are outside what we cover.

Conclusion

Brain zaps are real and documented. They are neither imaginary nor trivial. The best current reading of the evidence is that they reflect a nervous system adjusting to a drop in drug level faster than it can comfortably manage, and that the useful response is to revisit the pace of the reduction with a clinician rather than to endure them. Whether to reduce a medication at all is your decision, made with the clinician who knows your history. If you do, the size of each step and the time between steps are parts a clinician can adjust with you.

How Outro Health Approaches Brain Zaps During a Taper

Outro Health is a telehealth practice for people who want support coming off antidepressants and some other psychiatric medications. Our clinicians are trained in hyperbolic tapering by world-leading experts, take over the prescription during the taper, track withdrawal symptoms such as brain zaps between appointments, and work with compounding pharmacies when doses smaller than the lowest tablet are needed. When symptoms tell us the pace is too fast, the plan changes. Outro Health's tapering program is currently available to patients in more than a dozen states, including California, Florida, New York, Texas and more, and this article is here for anyone, wherever they are. If you would like to find out whether an evaluation fits your situation, you can read more about the Taper Management Program.